UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1471-1
Program Prior Authorization/Notification
Medication Crenessity™(crinecerfont) oral capsule and oral suspension
P&T Approval Date 2/2025
Effective Date 4/1/2025
1. Background:
Crenessity (crinecerfont) is a corticotropin-releasing factor type 1 receptor antagonist indicated
as adjunctive treatment to glucocorticoid replacement to control androgens in adults and
pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
2. Coverage Criteriaa:
A. Initial Authorization
1. Crenessity will be approved based upon all of the following criteria:
a. Diagnosis of classic congenital adrenal hyperplasia (CAH)
-AND-
b. Patient is 4 years of age or older
-AND-
c. Patient will receive concomitant glucocorticoid replacement (e.g., dexamethasone,
hydrocortisone, methylprednisolone, prednisone, prednisolone)
Authorization will be issued for 12 months.
B. Reauthorization
1. Crenessity will be approved based upon both of the following criteria:
a. Documentation of positive clinical response to Crenessity therapy
-AND-
b. Patient will continue to receive concomitant glucocorticoid replacement (e.g.,
dexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone)
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. Reference:
1. Crenessity [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.; December 2024.
Program Prior Authorization/Notification - Crenessity (crinecerfont)
Change Control
2/2025 New program
© 2025 UnitedHealthcare Services, Inc.
2